HEMEO welcomes new CEO

Since January 2024, HEMEO has had the great pleasure to welcome Leslie “Lee” DeGeer as its President and Chief Executive Officer. Lee is a seasoned medical device executive with more than 25 years of documented success in the Life Sciences and Diagnostics space, and with a proven track record of leading businesses to outperform the market.

After serving 10 years as a US army officer, Lee’s career background includes 15 years at Ventana Medical Systems / Roche Tissue Diagnostics, where he held multiple sales and marketing positions, including both leading their North American Marketing organization and where he was responsible for all ex-US commercialization efforts, post the acquisition of Ventana by Roche. After Ventana, Lee’s spent 6 years at Leica Biosystems (a Danaher OPCO), leading all North American Sales efforts and later was the Global Head of their Advanced Staining Reagent team. Lee then held the position of Chief Commercial Officer for HemoSonics, a medical device technology company focused on acute bleeding management, where he designed and executed their global commercial launch strategy. Most recently, Lee was President of Biocartis US, Inc, a privately held molecular diagnostics company, where he built the US organization and strategy, and where he and his team exceeded market expectations over the last 3 years.

In each endeavor, Lee has consistently demonstrated the ability to identify strategies that create sustainable competitive advantage, delivering results through rigorous execution and a continuous focus on building and enabling high performing, engaged and diverse teams.

Share this post: